July 10, 2019
TOKYO, JAPAN - July 10, 2019 - Terumo Corporation (TSE: 4543) today announced the launch of MISAGO™ RX Self-expanding Peripheral Stent for the use in iliac arteries, in mid-July. The product will be used for the treatment of peripheral artery disease (PAD) in the Japanese market.
Terumo initially introduced MISAGO as the world's first RX self-expanding stent system for the superficial femoral artery (SFA). This time, MISAGO has newly obtained additional market approval for the use in iliac arteries along with the original SFA approval. As such, a hydrophilic coating on the distal tip and the stent sheath has been added to the design, intended for an even smoother access to the lesion. Moreover, further extension of the product is in line for future launch ― a stent system with a longer shaft, designed to access peripheral lesions from the radial artery.
PAD is a disease where cholesterol, fatty deposits and/or calcium known as plaque, narrow or block arteries limiting blood flow to the limbs. The result can cause leg pain, cramping and difficulty walking. More severe symptoms may cause complications such as chronic skin ulceration, gangrene, leg amputation, infection and death.
Stent therapy is currently the gold standard for PAD patients with iliac arterial lesion. Terumo will aim to acquire 25% local market share, as this new additional launch will help Terumo provide wider treatment options for physicians in interventional therapy.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with approximately US$6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.
Corporate Communication Dept., Terumo Corporation
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.